Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this offering. Some of the information contained in this discussion and analysis, including information regarding the strategy and plans for our business, includes forward-looking statements that involve risks and uncertainties. You should review the "Risk Factors" section for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

Ground Breaking Cancer Treatment: Tumors Vanish Within Few Days

Milestones

SynergyMed Devices Inc. was incorporated in the State of Delaware in September 2019.

Since then, we have:

• Signed LOI's from Boston Scientific and Medtronic.
• $100 million projected revenue within 5 years (not guaranteed).
• 10 minute non-invasive treatment to cure cancer in dogs and mice.
• Building collaborations with leading U.S. institutions including Ohio State and Harvard.

The Company is subject to risks and uncertainties common to early-stage companies. Given the Company’s limited operating history, the Company cannot reliably estimate how much revenue it will receive in the future.

Historical Results of Operations

• Revenues & Gross Margin. For the period ended December 31, 2024, the Company had revenues of $0 compared to the year ended December 31, 2023, when the Company had revenues of $0.
• Assets. As of December 31, 2024, the Company had total assets of $101,122, including $85,743 in cash. As of December 31, 2023, the Company had $48,713 in total assets, including $40,984 in cash.
• Net Loss. The Company has had net losses of $48,801 and net losses of $23,178 for the fiscal years ended December 31, 2024 and December 31, 2023, respectively.
• Liabilities. The Company's liabilities totaled $86,110 for the fiscal year ended December 31, 2024 and $1,900 for the fiscal year ended December 31, 2023.

Liquidity & Capital Resources

To-date, the company has been financed with $140,500 in equity.

After the conclusion of this Offering, should we hit our minimum funding target, our projected runway is 6 months before we need to raise further capital.

We plan to use the proceeds as set forth in this Form C under "Use of Funds". We don’t have any other sources of capital in the immediate future.

We will likely require additional financing in excess of the proceeds from the Offering in order to perform operations over the lifetime of the Company. We plan to raise capital in 5 months. Except as otherwise described in this Form C, we do not have additional sources of capital other than the proceeds from the offering. Because of the complexities and uncertainties in establishing a new business strategy, it is not possible to adequately project whether the proceeds of this offering will be sufficient to enable us to implement our strategy. This complexity and uncertainty will be increased if less than the maximum amount of securities offered in this offering is sold. The Company intends to raise additional capital in the future from investors. Although capital may be available for early-stage companies, there is no guarantee that the Company will receive any investments from investors.

Runway & Short/Mid Term Expenses

SynergyMed Devices Inc. cash in hand is $125,000, as of April 2025. Over the last three months, revenues have averaged $0/month, cost of goods sold has averaged $0/month, and operational expenses have averaged $15,000/month, for an average burn rate of $15,000 per month. Our intent is to be profitable in 6 months.

In January, the company won a grant of $200K to convert its existing prototype into a product.

We don't expect to generate revenue in the next 3-6 months. We hope to generate revenue by quarter 2 or 3 in 2025.  It is difficult to quantify the revenues but we expect about $100k per month to begin with in 2025. If we meet our target of raising $500K, then the expenses in the next 3-6 months will be as follows: 
Large Animal Studies=$146,500
Build Veterinary Product=$137,000
Veterinary Product Marketing=$93,500
FDA Pre-Sub Meeting=$40,500
Start First in Human Studies=$82,500

We are not yet profitable, we are in the product development finishing phase. We spent the last year converting our prototype into product and now we are at the stage of certifying the product to make it ready for sales. Our financial projection model indicates that we will become profitable by 2027 when we have generated more revenue than the cost. This will happen when we have sold over 50 devices for the veterinary market with their consumables at a rate of 8 patients per month.

A grant we won for $200K. We hope to extend the grant with amount of $100 to $130K. We are also applying to other scientific grants and talking to large venture capital investors. 

All projections in the above narrative are forward-looking and not guaranteed.